Does Medicare Cover Zepbound? Weight Loss, Sleep Apnea, and the GLP-1 Bridge

Medicare does not cover Zepbound for weight loss alone

If your goal is weight loss or weight management, Medicare Part D plans are not allowed to cover Zepbound (tirzepatide). This is not a plan-by-plan choice — it is written into federal law. The Social Security Act excludes from Part D coverage any 'agents when used for anorexia, weight loss, or weight gain.' That exclusion has been in place since the 2003 Medicare Modernization Act created the Part D drug benefit.

In April 2025, CMS finalized a decision NOT to move forward with a proposal that would have reinterpreted the law to allow Part D plans to cover anti-obesity medications. As a result, weight-loss-only coverage of drugs like Zepbound remains excluded for 2026, outside the temporary GLP-1 Bridge described below.

The only way standard Part D can pay for an anti-obesity drug is when it is prescribed for a separate, medically accepted indication other than weight loss itself. That distinction is the key to understanding everything below.

Part D may cover Zepbound for obstructive sleep apnea (OSA)

In December 2024, the FDA approved Zepbound to treat moderate-to-severe obstructive sleep apnea in adults who also have obesity — the first medication ever approved for OSA. Because this is a medical indication that is separate from weight loss, a Medicare Part D or Medicare Advantage (Part C) plan is permitted to cover Zepbound for it.

Coverage is not automatic, and it varies from plan to plan. To have a realistic chance of approval, you generally need to meet all of the following:

• An OSA diagnosis, typically documented by a sleep study.
• Your specific plan must list Zepbound on its formulary (drug list).
• Prior authorization from the plan is generally required before it will pay.
• Coverage and cost-sharing differ by plan — confirm the details in your plan's Evidence of Coverage or formulary before assuming it is covered.

The Medicare GLP-1 Bridge: a temporary path for weight reduction

CMS launched a demonstration called the Medicare GLP-1 Bridge that, for the first time, makes certain GLP-1 medicines available to eligible Part D beneficiaries specifically for weight reduction. The Bridge covers the Zepbound KwikPen formulation, all formulations of Wegovy, and Foundayo.

The program is temporary and runs from July 1, 2026 through December 31, 2027. CMS designed it as a short-term 'bridge,' and as of mid-2026 there is no confirmed Part D coverage pathway scheduled to replace it once it ends (see below).

Cost is a major reason this matters. Under the Bridge, eligible members pay a flat $50 copayment per 30-day supply, and that copay does not increase as your dose increases. Access requires your prescriber to submit a prior-authorization request and a prescription for a covered use.

• Eligibility is based on BMI: a BMI of 35 or more on its own, OR a BMI of 30 or more with a weight-related condition, OR a BMI of 27 or more with a weight-related condition.
• You must be enrolled in a Medicare Part D plan to participate.
• The $50 copay does NOT count toward your Part D deductible.
• The $50 copay also does NOT count toward your Part D true out-of-pocket (TrOOP) costs or the 2026 Part D annual out-of-pocket cap of $2,100.
• Low-income subsidy (Extra Help) does not reduce the $50 Bridge copay.
• The Bridge copay is separate from, and in addition to, your regular Part D premium (the 2026 national base beneficiary premium is $38.99/mo; your actual premium varies by plan).
• Your prescriber and plan confirm whether you meet the requirements.

What happens after 2027? The BALANCE Model status

Because the GLP-1 Bridge ends December 31, 2027, many people want to know what comes next. CMS had described a longer-term, voluntary demonstration called the BALANCE Model (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) as a possible successor for Part D.

However, in April 2026 CMS announced it would NOT launch the BALANCE Model in Medicare Part D — the required level of Part D plan participation was not met, and the agency extended the GLP-1 Bridge through the end of 2027 in part to gather more data. As a result, there is currently no confirmed Part D pathway to continue weight-loss GLP-1 coverage after the Bridge ends.

Treat the Bridge as a defined, time-limited opportunity rather than a permanent benefit. Coverage of GLP-1s for weight loss after 2027 is uncertain, so watch for CMS and plan announcements during future Open Enrollment periods.

What Zepbound costs, and cash-pay options

If Medicare does not cover Zepbound for your situation and you do not qualify for the Bridge, the cost can be steep. At retail pharmacies without insurance, Zepbound can cost more than $1,000 per month.

The drugmaker, Eli Lilly, offers a self-pay program called LillyDirect that prices single-dose Zepbound vials below retail. The figures below are cash-pay prices independent of Medicare, and they change over time — confirm current pricing at LillyDirect before relying on them:

• About $299/mo for the 2.5 mg vial (with timely refills).
• About $399/mo for the 5 mg vial.
• About $449/mo for the 7.5 mg through 15 mg vials.
• These are self-pay prices and do not run through your Medicare plan, so they will not count toward your Part D deductible or out-of-pocket cap.

Other weight-loss drugs and your right to appeal

The same rules apply to similar medications. Wegovy and Ozempic (and Zepbound) cannot be covered by standard Part D for weight loss alone, but may be covered when prescribed for a different approved medical indication — for example, certain GLP-1 drugs are approved to reduce cardiovascular risk or to treat type 2 diabetes. Wegovy is also among the medicines included in the GLP-1 Bridge for weight reduction.

If your plan denies Zepbound, you have the right to appeal. Start by asking your prescriber to request a coverage determination or prior authorization with supporting documentation (such as your OSA sleep study). If that is denied, you can file a formal appeal through your plan; the denial notice will explain the deadlines and steps. A licensed Medicare advisor or your plan's member services line can walk you through it.

Because formularies, prior-authorization rules, and Bridge participation differ from plan to plan, always confirm your specific coverage in your plan's Evidence of Coverage before filling a prescription.